###begin article-title 0
Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 316 322 316 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
The purpose of our study was to compare differences in the prognosis of breast cancer (BC) patients at high (H) risk or intermediate slightly (IS) increased risk based on family history and those without a family history of BC, and to evaluate whether ten-year overall survival can be considered a good indicator of BRCA1 gene mutation.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 285 293 285 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2 </italic>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
We classified 5923 breast cancer patients registered between 1988 and 2006 at the Department of Oncology and Haematology in Modena, Italy, into one of three different risk categories according to Modena criteria. One thousand eleven patients at H and IS increased risk were tested for BRCA1/2 mutations. The overall survival (OS) and disease free survival (DFS) were the study end-points.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 259 265 259 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 279 284 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA-</italic>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
###xml 161 166 <span type="species:ncbi:9606">women</span>
Eighty BRCA1 carriers were identified. A statistically significantly better prognosis was observed for patients belonging to the H risk category with respect to women in the IS and sporadic groups (82% vs.75% vs.73%, respectively; p < 0.0001). Comparing only BRCA1 carriers with BRCA-negative and sporadic BC (77% vs.77% vs.73%, respectively; p < 0.001) an advantage in OS was seen.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 239 245 239 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 413 419 413 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 162 167 <span type="species:ncbi:9606">women</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 440 445 <span type="species:ncbi:9606">women</span>
Patients belonging to a population with a high probability of being BRCA1 carriers had a better prognosis than those with sporadic BC. Considering these results, women who previously had BC and had survived ten years could be selected for BRCA1 analysis among family members at high risk of hereditary BC during genetic counselling. Since only 30% of patients with a high probability of having hereditary BC have BRCA1 mutations, selecting women with a long term survival among this population could increase the rate of positive analyses, avoiding the use of expensive tests.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2 </italic>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 278 283 278 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 403 409 403 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 495 496 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 497 498 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 509 515 509 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2 </italic>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 622 628 622 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 715 720 715 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 875 876 875 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 877 879 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 959 965 959 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1449 1455 1449 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 1557 1558 1557 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 167 172 <span type="species:ncbi:9606">women</span>
###xml 267 272 <span type="species:ncbi:9606">women</span>
###xml 370 375 <span type="species:ncbi:9606">women</span>
###xml 460 465 <span type="species:ncbi:9606">women</span>
###xml 1209 1217 <span type="species:ncbi:9606">patients</span>
###xml 1421 1429 <span type="species:ncbi:9606">patients</span>
The major breast cancer (BC) predisposing genes, BRCA1 and BRCA2 were identified in 1994 and 1995, respectively [1,2]. Unfortunately, the optimal clinical approach to women who develop hereditary breast cancer remains incompletely defined. Studies of the outcomes of women with BRCA1/BRCA2-related cancer have yielded conflicting results. Several reports suggested that women with germline mutations in BRCA1 are more likely to die from their disease than are women with sporadic breast cancer [3-6], whereas BRCA2 mutation carriers and non-mutation carriers seem to share a similar prognosis [7,8]. The poor prognosis in BRCA1 carriers may be consistent with the histological characteristics usually described for BRCA1-associated breast cancer, which show higher histologic grade and cancers that are more often hormone receptor-negative than sporadic breast cancer cases [9-12]. However, Bonadona et al. found no evidence for poorer short-term survival in BRCA1 mutation carriers compared with non-carriers in a prospective population-based cohort [13]. Apart from a simple interest in the epidemiological aspects of breast malignancy, knowledge of the associated mortality is important to the families of patients with BC and to clinicians and scientists involved in trying to improve the outcomes of breast cancer. The results of a recent study in an Ashkenazi Jewish population suggested that among the subgroup of patients with BC carrying a BRCA1 mutation, those who received chemotherapy had a better survival rate compared with those who did not [8].
###end p 10
###begin p 11
###xml 385 389 385 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 403 408 403 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA-</italic>
###xml 671 677 671 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 757 763 757 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 862 868 862 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 633 641 <span type="species:ncbi:9606">patients</span>
###xml 909 916 <span type="species:ncbi:9606">patient</span>
###xml 936 944 <span type="species:ncbi:9606">patients</span>
The primary aim of our study was to calculate disease free survival (DFS) and overall survival (OS) of BC patients at high risk (H) or intermediate slightly (IS) increased risk based on family history and those without a family history of breast cancer using the population registered with the Breast Cancer Registry in Modena. Previous studies were aimed at evaluating the outcome in BRCA-positive and BRCA-negativepatients, but none showed a significant survival difference between different risk categories. In case of statistically significant differences in OS between the three groups, a secondary aim was to determine whether patients with a better prognosis were BRCA1 mutation carriers, showing that the outcome could be considered an indicator of BRCA1 inheritance. Additionally, we evaluated whether chemotherapy could play a role in the prognosis of BRCA1 carriers, providing more benefit in this patient population than in patients with sporadic breast cancer.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 13
###begin p 14
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 185 193 <span type="species:ncbi:9606">patients</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
###xml 624 632 <span type="species:ncbi:9606">patients</span>
###xml 760 768 <span type="species:ncbi:9606">patients</span>
Patients included in our analysis were diagnosed between 1988 and 2006 at the Department of Oncology and Haematology in Modena. All newly-diagnosed, biopsy-proven primary breast cancer patients were evaluated. The family history was collected and classified according to the Modena criteria (without family history, IS increased risk, or H risk)[14] and a blood sample, preserved with EDTA, was obtained with informed consent and frozen at -80degreesC for biological studies. On the basis of the Modena criteria for familial risk, patients who did not have any family history were considered to have sporadic breast cancer, patients with one or two breast cancers at >/= 40 years, without a first-degree relationship, were considered at IS increased risk, and patients with breast cancer at </= 35 years, three or more breast cancers with a first-degree relationship, and at least one case at </= 40 years or bilateral breast cancer had a H risk of being hereditary.
###end p 14
###begin p 15
All research regarding the identification, counselling, genetic testing, and clinical data regarding individuals at risk of developing breast cancer were ethically approved by the Ethics Commitee of Modena (reference number 45/00).
###end p 15
###begin title 16
Mutational analysis
###end title 16
###begin p 17
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
In 1995, DNA started to be extracted from frozen whole blood using the Invisorb Blood Universal kit (Invitek, Berlin, Germany), amplified by PCR using primers specific for the coding sequence and exon-intron boundaries of BRCA1, and analyzed by Direct Automated Sequencing using an ABI Prism 3100 (Applied Biosystems, Foster City, CA). Subsequently, patients with breast cancer provided consent for genetic testing that was completed for each case.
###end p 17
###begin p 18
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
Samples negative for BRCA1 mutations were tested for BRCA1 rearrangements using the multiplex ligation-dependent probe amplification assay (MRC Holland, Amsterdam, The Netherlands) following the manufacturer's protocol.
###end p 18
###begin title 19
Statistical analysis
###end title 19
###begin p 20
###xml 7 9 5 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
###xml 221 227 219 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 595 601 593 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 203 211 <span type="species:ncbi:9606">Patients</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
The chi2 test was used to determine differences in clinicopathological features between groups. Survival curves were estimated using the Kaplan-Meier method including the log-rank test group comparison. Patients who were BRCA1 carriers were matched with patients with sporadic breast cancer from the Modena cancer registry. This registry, initiated in 1988, covers an area with approximately 650,000 inhabitants in Northern Italy. A database with a total of 3858 cases of sporadic breast cancer was used to find four matched controls for each case and a randomized matches were assigned between BRCA1 and patients with sporadic BC of the same age at diagnosis (range, between 26 and 76 +/- 4 years), tumour grade (I, II, and III), and stage (I, II, and III). Multivariate analyses of DFS and OS were conducted using a proportional hazards Cox regression model. All statistical analyses were done with SPSS, version 12.0 (SPSS Inc, Chicago, IL).
###end p 20
###begin title 21
Results
###end title 21
###begin title 22
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Characteristics
###end title 22
###begin p 23
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 392 394 392 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 510 512 510 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 630 632 630 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1053 1055 1053 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1198 1200 1198 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1595 1597 1595 1597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
###xml 1081 1089 <span type="species:ncbi:9606">patients</span>
###xml 1436 1444 <span type="species:ncbi:9606">patients</span>
From January 1988 and December 2006, 5923 patients were diagnosed with breast cancer. According to their family history, 4912 were considered sporadic breast cancers, 691 were at IS increased risk, and 320 were considered H risk. The patients' characteristics are detailed in Table 1. The H risk group presented with a medullary carcinoma histotype more frequently than the other two groups (p < .0001). The H risk group was more likely to have stage II disease than the sporadic and IS increased risk groups (p < .0001), and to have a significantly lower estrogen receptor (ER) and progesterone receptor (PgR) expression levels (p < .0001) as measured by immunohistochemical analysis (clone 6F11, Ventana, for ER; and clone 1E2, Ventana, for PgR) and stained by Ventana Benchmark autostainer. The ER and PgR receptor status was tested by evaluating the percentage of nuclear immunoreactivity with respect to all the nuclei in the neoplastic cells, independently of the staining intensity. No differences were seen in the Ki67 level between the groups (p = .17). The proportion of patients who received adjuvant chemotherapy was greater in the IS increased risk group than in the other two groups (p < .0001). The most frequent chemotherapy strategy was anthracycline-based followed by taxanes and the CMF regimen. The most frequently used first line chemotherapy regimen was platinum based, followed by a CMF scheme. The proportion of patients who received adjuvant hormone therapy was lower in the H risk group than in the other two groups, according to the negative hormonal receptor status (p < .0001).
###end p 23
###begin p 24
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Clinicopathological characteristics of patients according to familial risk group
###end p 24
###begin p 25
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor
###end p 25
###begin title 26
Mutational Analysis
###end title 26
###begin p 27
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
The BRCA1 mutational analysis was only performed in patients belonging to the H and IS risk groups, with a 22.8% (73/320) and 1.0% (7/691) mutation rate, respectively. In total, 80 patients were BRCA1 carriers.
###end p 27
###begin title 28
Survival analysis
###end title 28
###begin p 29
###xml 442 444 442 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1A</xref>
###xml 612 614 612 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1C</xref>
###xml 690 696 690 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 729 734 729 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA </italic>
###xml 751 757 751 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 933 938 933 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA </italic>
###xml 1037 1043 1037 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 1061 1065 1061 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 1130 1132 1130 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1145 1147 1145 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1B</xref>
###xml 1212 1216 1212 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 1251 1255 1251 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 1273 1275 1273 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1287 1289 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1D</xref>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 336 344 <span type="species:ncbi:9606">patients</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
###xml 662 670 <span type="species:ncbi:9606">patients</span>
###xml 1075 1083 <span type="species:ncbi:9606">patients</span>
###xml 1226 1234 <span type="species:ncbi:9606">patients</span>
Overall, 5923 patients were followed until December 2006, resulting in a median follow-up time of 72 months. In all, 1302 deaths (1074 sporadic, 174 IS increased risk, and 54 H risk) and 1137 relapses (884 sporadic, 186 IS increased risk, and 67 H risk) were reported. The estimated 10-year overall survival rate was 82% for the H risk patients, 75% for the IS increased risk group, and 73% for patients with sporadic breast cancer (log-rank p < .0001; Fig. 1A). The estimated 10-year DFS was 72% in the H risk group, 70% in the IS increased risk group, and 75% in patients with sporadic breast cancer (log-rank p = .12; Fig. 1C). After the genetic analysis, 80 patients were classified as BRCA1 carriers and 931 were considered BRCA negative. In the BRCA1 carrier group, 8 deaths (5 caused by a second tumour arising after breast cancer) and 13 relapses (6 local recurrences and 7 distant recurrences) were reported, whereas in the BRCA negative group 220 deaths and 240 relapses occurred. The 10-year overall survival rate was 77% for BRCA1 carriers, 77% for BRCA-negative patients, and 73% for sporadic breast cancer (log-rank p < .001; Fig. 1B). The 10-year DFS was 75% in sporadic breast cancer, 70% in the BRCA-negative patients, and 70% in the BRCA1 group (log-rank p = .45; Fig. 1D).
###end p 29
###begin p 30
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 0 100 0 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Overall survival and disease free survival according to risk group (A, C) and to <italic>BRCA1 </italic>status (B, D)</bold>
Overall survival and disease free survival according to risk group (A, C) and to BRCA1 status (B, D).
###end p 30
###begin p 31
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 264 270 264 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 333 335 333 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
The study group of 80 BRCA1 cases was compared with 320 matched sporadic cases from the Modena cancer registry which were the same age, and had the same tumour grade and stage. Results are shown in Fig. 2. A statistically significant difference in OS was seen for BRCA1 patients compared with sporadic BC (85% vs. 73%, respectively, p = .05).
###end p 31
###begin p 32
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 0 167 0 167 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Probability of survival in 80 <italic>BRCA1 </italic>breast cancer cases and 320 sporadic breast cancer controls matched for age and tumour grade and stage, using Kaplan-Meier analysis</bold>
###xml 257 259 257 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
Probability of survival in 80 BRCA1 breast cancer cases and 320 sporadic breast cancer controls matched for age and tumour grade and stage, using Kaplan-Meier analysis. There was a statistically significant difference between the two groups (log-rank test, p = .05).
###end p 32
###begin p 33
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 146 151 146 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3A, B</xref>
###xml 247 253 247 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 265 270 265 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3C, D</xref>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
According to the hormone receptor status, the hormone receptor-negative patients in the H risk group and the BRCA1 patients had a better OS (Fig. 3A, B) while a hormone receptor-positive advantage was only seen in the H risk group, but not in the BRCA1 group (Fig. 3C, D).
###end p 33
###begin p 34
###xml 127 133 127 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 0 207 0 207 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Overall survival according to risk group in hormone receptor negative (A) and positive (C) patient subgroups, and according to <italic>BRCA1 </italic>status in hormone receptor negative (B) and positive (D) patient subgroups</bold>
###xml 91 98 <span type="species:ncbi:9606">patient</span>
###xml 190 197 <span type="species:ncbi:9606">patient</span>
Overall survival according to risk group in hormone receptor negative (A) and positive (C) patient subgroups, and according to BRCA1 status in hormone receptor negative (B) and positive (D) patient subgroups.
###end p 34
###begin title 35
Multivariate survival analysis according to prognostic factors and chemotherapy
###end title 35
###begin p 36
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 170 176 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 270 272 270 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 294 296 294 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 439 441 439 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 462 464 462 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 573 575 573 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 607 609 607 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 646 648 646 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 880 885 878 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 914 916 912 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 931 935 929 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 1034 1036 1032 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1106 1108 1104 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1183 1185 1181 1183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1222 1224 1220 1222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1382 1384 1378 1380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1441 1446 1437 1442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1527 1529 1523 1525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1551 1557 1547 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1-</italic>
###xml 1618 1620 1614 1616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1660 1662 1656 1658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1696 1698 1692 1694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1743 1745 1739 1741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1802 1804 1798 1800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1841 1843 1837 1839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1977 1978 1973 1974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 847 855 <span type="species:ncbi:9606">patients</span>
Of the 5923 patients, 5012 were included in multivariate analyses, which included BRCA1 status, disease stage, ER status, PgR status, grading, age, and chemotherapy. The BRCA1 positive and negative status was a significant independent factor for improved OS (HR = 0.29; p = .002 and HR = 0.76; p = < .001, respectively) compared with the sporadic breast cancer cases. Positive ER and PgR status was associated with a better OS (HR = 0.82; p = .03 and HR = 0.79; p = .004, respectively). Also, chemotherapy was an important factor in reducing the mortality rate (HR = 0.68; p < .0001). Stage > I (HR = 3.49; p < .0001) and grading III (HR = 1.39; p < .0001) were significant factors for poorer OS. Younger age (</= 35 years) represented a risk factor for a shorter OS, but the trend was not statistically significant. In a model that included 2213 patients receiving chemotherapy, BRCA1-positive status (HR = 0.38; p = .05) but not BRCA1-negative status (HR = 0.97; p = .79) reduced the mortality rate. Positive PgR status (HR = 0.76; p = .021) was a favourable factor as was positive ER status (HR = 0.76; p = .083), but did not reach statistical significance. Stage > I (HR = 3.55; p < .0001) and grading III (HR = 1.38; p < .0001) were factors statistically associated with an increased risk of death. There was a similar but non significant trend in age </= 35 years (HR = 1.15; p = .44). Conversely, in a model without chemotherapy, the BRCA1-positive status lost statistical significance in reducing mortality (HR = 0.23; p = 0.056), whereas the BRCA1-negative status maintained its favourable impact (HR = 0.56; p < .0001). Also, positive ER (HR = 0.82, p = .17) and PgR status (HR = 0.82; p = .08) and age less than 35 years (HR = 0.95;p = .85) did not affect OS. Finally, stage > 1 (HR = 3.43; p < .0001) and grading III (HR = 1.39; p < .0001) were statistically associated with an increased risk of death. Detailed results for multivariate analysis are shown in Table 2.
###end p 36
###begin p 37
Cox's proportional hazard regression models for overall survival
###end p 37
###begin p 38
Abbreviations: HR, hazard ratio; CI, confidence interval
###end p 38
###begin p 39
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
In comparing BRCA1 patients who did or did not receive chemotherapy, no difference was seen in terms of OS (see Fig. 4), even if all the death events in the treated group of patients were derived from second tumours (4 cases).
###end p 39
###begin p 40
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 153 155 153 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 0 161 0 161 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A comparison of the group of <italic>BRCA1 </italic>patients who received or did not receive chemotherapy did not show any difference in overall survival (log-rank test, <italic>p </italic>= .69)</bold>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
A comparison of the group of BRCA1 patients who received or did not receive chemotherapy did not show any difference in overall survival (log-rank test, p = .69).
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 235 241 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 266 271 266 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 344 350 344 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
###xml 452 460 <span type="species:ncbi:9606">patients</span>
###xml 501 509 <span type="species:ncbi:9606">Patients</span>
The results of this large analysis show that patients considered at H risk of being BRCA1 carriers had a better OS than patients considered at IS increased risk or to have sporadic breast cancer. This difference was also maintained in BRCA1 carriers with respect to BRCA1-negative and sporadic breast cancer patients. Notably, 91.2% (73/80) of BRCA1 carriers were identified in the H risk group, and may explain the survival advantage in this group of patients, even if other reasons may be involved. Patients who know they are at high risk of developing breast cancer may be more likely to participate in surveillance programs and start at a younger age, receive an earlier diagnosis, and subsequently, experience a better outcome.
###end p 42
###begin p 43
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 551 557 551 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1-</italic>
###xml 607 613 607 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 759 765 759 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 134 141 <span type="species:ncbi:9606">patient</span>
###xml 177 185 <span type="species:ncbi:9606">patients</span>
###xml 316 323 <span type="species:ncbi:9606">patient</span>
###xml 337 342 <span type="species:ncbi:9606">woman</span>
###xml 659 664 <span type="species:ncbi:9606">women</span>
One of the most important findings of our study was that the survival difference was attributable, in a multivariate analysis, to the patient's BRCA1 status and was observed in patients treated with chemotherapy. This finding is important when, as happens in a family cancer centre like in ours, we are faced with a patient or a healthy woman who has a family history of breast cancer. By collecting all the information about individuals affected by breast cancer, very long-term survivors can be identified by predicting a predisposition for being a BRCA1-mutation carrier in the descendants. Furthermore, BRCA1 carriers may be more likely to be found among women who have a high probability of hereditary breast cancer and who have a long term survival. If BRCA1 carriers could be identified through these characteristics, the use of expensive tests could be avoided and the rate of positive analyses increased.
###end p 43
###begin p 44
###xml 179 185 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 332 338 332 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
Our study involves a very large number of Caucasian patients with breast cancer (N = 5923) who were first evaluated for their family history of breast cancer and subsequently for BRCA1 status. The most common weakness of previous studies includes the small number of patients or selection bias, such as a retrospective analysis for BRCA1 status. Owing to the large number of subjects, we could calculate OS differences between risk groups, and even in subgroup analyses.
###end p 44
###begin p 45
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 375 380 375 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA </italic>
###xml 418 424 418 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 437 441 437 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 512 518 512 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 905 910 905 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA-</italic>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 951 957 951 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 451 459 <span type="species:ncbi:9606">patients</span>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
###xml 579 587 <span type="species:ncbi:9606">patients</span>
###xml 957 965 <span type="species:ncbi:9606">patients</span>
Unexpectedly, the survival difference according to H risk and BRCA1 status was not related to the DFS. This finding shows that the H risk and BRCA1 patients have the same DFS as the other two groups, but seem to respond better to chemotherapeutic agents. This finding is in contrast with the results of Rennert et al. [8] who showed an insignificant difference in OS between BRCA carriers and non carriers and between BRCA1 carriers and BRCA-negative patients treated with chemotherapy. Our argument is that, in BRCA1 patients, 41% of relapses were local recurrences, whereas in patients with sporadic BC the local recurrence rate was 25%, and distant metastases accounted for 75%. Consequently, it is not surprising that a difference in OS was found and could be explained by the use of alkylating agents, such as platinum-derived drugs, in metastatic disease that are well known to be more effective in BRCA-related tumours [15]. Furthermore, since BRCA1 patients maintain a statistically significant OS advantage, even after matching each case to four controls for age and tumour grade and disease stage, this result is very important in terms of its practical value, because all confounders have been removed.
###end p 45
###begin p 46
###xml 14 16 14 16 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 147 152 <span type="species:ncbi:9606">women</span>
###xml 198 203 <span type="species:ncbi:9606">women</span>
Robson et al [12] suggested that a BRCA1 mutation was an independent predictor of breast cancer mortality in a multivariate analysis of a group of women who did not receive chemotherapy, but not in women who received adjuvant chemotherapy.
###end p 46
###begin p 47
###xml 153 159 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1-</italic>
###xml 389 395 389 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 717 723 717 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 772 776 772 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 844 849 844 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1039 1045 1039 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
###xml 528 536 <span type="species:ncbi:9606">patients</span>
###xml 755 763 <span type="species:ncbi:9606">patients</span>
###xml 1088 1096 <span type="species:ncbi:9606">patients</span>
In a multivariate analysis, we found that chemotherapy is a prognostic factor for better survival in all patients combined; furthermore, we found that a BRCA1-positive status was an independent predictor for a better survival in all patients and also in the subgroup of patients who received chemotherapy, but not in patients who did not receive chemotherapy. No differences are shown for BRCA1 patients, independently of chemotherapy or not. Also, this result might be explained by the fact that deaths in the treated group of patients were all related to a second tumour, while in the non treated group one of three deaths was caused by breast cancer. In conclusion, chemotherapy has a greater protective effect in BRCA1 mutation carriers compared with patients who are BRCA-negative and those with sporadic breast cancer. Furthermore, since BRCA1-related tumours are more likely to be triple negative, the greatest advantage was shown for ER-negative breast cancer, were chemotherapy is the most active. Hence, increasing the number of BRCA1 carriers identified by correctly selecting patients with a high probability of having hereditary breast cancer through a 10-year survival analysis could improve the benefit derived from specific chemotherapy agents (i.e., alkylating or PARP-inhibitors).
###end p 47
###begin p 48
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2 </italic>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAD51 </italic>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 254 259 254 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA </italic>
###xml 523 528 523 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA </italic>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1162 1166 1162 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 1346 1351 1346 1351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA </italic>
###xml 1421 1425 1421 1425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 1525 1531 1525 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 1255 1263 <span type="species:ncbi:9606">patients</span>
###xml 1332 1340 <span type="species:ncbi:9606">patients</span>
###xml 1435 1443 <span type="species:ncbi:9606">patients</span>
In fact, the chemotherapy benefit is well known because normal BRCA1 and BRCA2 proteins participate with RAD51 in the repair of double-stranded DNA breaks induced by DNA-damaging agents [16-19]. The better prognosis could be due to the deficiency of the BRCA proteins, which confer substantial cellular sensitivity to the inhibition of poly (ADP-Ribose) polymerase enzyme (PARP). This polymerase is a key enzyme in the repair of single-stranded DNA damage via the base excision repair pathway. The loss of PARP activity in BRCA mutant cells might lead to the persistence of DNA lesions normally repaired by homologous recombination, resulting in increased chromosome instability and programmed cell death specifically in tumour cells [20,21]. Therefore, because there is no functional protein within the tumour cells, they lose their capacity to repair DNA damage. This might be specifically pronounced for drugs, such as cisplatin, acting through the induction of DNA damage leading to cell death and to a better therapeutic response. In a small clinical study, Chappuis et al [22] found a benefit in Ashkenazi Jews with locally advanced breast cancer who were BRCA-positive and treated with anthracycline-based chemotherapy regimens. In this study, all patients received anthracycline-based neoadjuvant chemotherapy, and 10 of 11 patients with BRCA mutations had a clinical complete response compared with only 8 of 27 BRCA-negative patients with sporadic breast tumours. From this study, it was inferred that tumours with BRCA1 mutations are highly sensitive to anthracycline-based chemotherapy regimens.
###end p 48
###begin p 49
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
###xml 474 482 <span type="species:ncbi:9606">patients</span>
###xml 670 678 <span type="species:ncbi:9606">patients</span>
In our study, patients were considered part of a hospital-based population and were not selected for age, tumour stage, or treatment, which could influence survival rates. We were successful in obtaining blood samples from all patients and were able to genotype all the samples we received. The patients were followed for a median of 72 months. Treatment regimens were chosen on the basis of disease staging. The Modena Cancer Registry captures outcome data from almost all patients with cancer who are treated in the province. Data on pathological diagnosis are verified by a pathologist, and incomplete information is retrieved from medical records when possible. All patients were Caucasian, and it is possible that the chemotherapy sensitivity can be associated with specific modifier genes not found in other populations.
###end p 49
###begin p 50
###xml 416 422 416 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
Our study has a number of limitations. Tumour stage and hormone receptor status were not routinely recorded, particularly during the first period. Since we tested only a subpopulation of patients with a positive family history of breast cancer, it is possible that some hereditary cases were misclassified; but we found that only 1% of mutations occurred in the IS increased risk group suggesting that the number of BRCA1 carriers in the sporadic group would be very low. Since we identified only 80 mutation carriers, the subgroup analysis relied on a small number of subjects.
###end p 50
###begin p 51
###xml 350 356 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 490 496 490 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 613 619 613 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
In conclusion, our study is the first to evaluate a relationship between familial risk of breast cancer and a genetic assessment in terms of DFS and OS. We propose that the increased survival associated with a family history of breast cancer, suggesting hereditary breast cancer according to the Modena criteria, should be considered with respect to BRCA1 analysis as a predictor of mutations. We feel that randomized studies need to be designed to further address the relationship between BRCA1 mutations and sensitivity to chemotherapy, and further clinical investigations are required to determine whether the BRCA1 status can be used to predict treatment outcomes.
###end p 51
###begin title 52
Conclusions
###end title 52
###begin p 53
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 210 216 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 324 330 324 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 296 301 <span type="species:ncbi:9606">women</span>
In conclusion, our data show that patients belonging to a population with a high probability of being BRCA1 carriers have a better prognosis than other risk groups, and this could be considered an indicator of BRCA1 inheritance. This paper provides, for the first time, evidence-based proof that women at high risk of being BRCA1 carriers have a favorable prognosis after 10 years follow-up.
###end p 53
###begin title 54
Competing interests
###end title 54
###begin p 55
The authors declare that they have no competing interests.
###end p 55
###begin title 56
Authors' contributions
###end title 56
###begin p 57
###xml 286 293 <span type="species:ncbi:9606">patient</span>
###xml 358 365 <span type="species:ncbi:9606">patient</span>
LC participated in the design of the study and drafted the manuscript. CM acquired the data and performed the statistical analysis. CC participated in the statistical analysis. VM performed the genetic testing. IM acquired the data from the centre. GC participated in the collection of patient data from Mantua Hospital. GP participated in the collection of patient data from Rimini Hospital.
###end p 57
###begin p 58
###xml 37 44 <span type="species:ncbi:9606">patient</span>
DT participated in the collection of patient data from Bologna Hospital. MF designed the study and revised the final manuscript. All authors read and approved the final manuscript.
###end p 58
###begin title 59
Pre-publication history
###end title 59
###begin p 60
The pre-publication history for this paper can be accessed here:
###end p 60
###begin p 61

###end p 61
###begin title 62
Acknowledgements
###end title 62
###begin p 63
###xml 53 57 <span type="species:ncbi:9319">Euro</span>
Associazione Angela Serra per la Ricerca sul Cancro; Euro Mediterranean Network for Genetic Services-Coordination Action (Grant to the Budget) - Contract ndegrees INCO-CT-2006-031968
###end p 63
###begin article-title 64
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
###end article-title 64
###begin article-title 65
Identification of the breast cancer susceptibility gene BRCA2
###end article-title 65
###begin article-title 66
###xml 77 82 <span type="species:ncbi:9606">women</span>
Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer
###end article-title 66
###begin article-title 67
Familial invasive breast cancers: worse outcome related to BRCA1 mutations
###end article-title 67
###begin article-title 68
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
###end article-title 68
###begin article-title 69
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data
###end article-title 69
###begin article-title 70
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients
###end article-title 70
###begin article-title 71
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations
###end article-title 71
###begin article-title 72
Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations
###end article-title 72
###begin article-title 73
BRCA1 dysfunction in sporadic basal-like breast cancer
###end article-title 73
###begin article-title 74
Basal-like breast cancer and the BRCA1 phenotype
###end article-title 74
###begin article-title 75
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
###end article-title 75
###begin article-title 76
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review
###end article-title 76
###begin article-title 77
###xml 27 32 <span type="species:ncbi:9606">women</span>
Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience
###end article-title 77
###begin article-title 78
###xml 71 76 <span type="species:ncbi:9606">human</span>
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
###end article-title 78
###begin article-title 79
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
###end article-title 79
###begin article-title 80
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells
###end article-title 80
###begin article-title 81
The relationship between the roles of BRCA genes in DNA repair and cancer predisposition
###end article-title 81
###begin article-title 82
The role of BRCA1 in the cellular response to chemotherapy
###end article-title 82
###begin article-title 83
Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining
###end article-title 83
###begin article-title 84
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
###end article-title 84
###begin article-title 85
A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer
###end article-title 85

